Perfect Match study
"The Perfect Match"
Improving access to advanced therapies for people living with drug-resistant epilepsy
Approximately 90,000 Australians live with drug-resistant epilepsy. This means they experience ongoing seizures, despite taking antiseizure medications. They may be eligible for advanced epilepsy therapies. These include epilepsy surgery, neuromodulation, and ketogenic diet. We know at a population-level, these advanced therapies can be very effective and safe. But we do not know which therapies will be best for individual patients. We also don't have a way of balancing this selection against an individual's preferences, like treatment cost, number of hospital visits required, and so on.
Our multidisciplinary team aims to address this clinical need by creating a clinical decision-support tool.
Through interviews with many Australians living with epilepsy, as well as integrating data from clinical trials, we will create a tool that can help guide clinicians and patients towards the advanced therapy that is likely to be most effective and acceptable for them.
Monash University Human Research Ethics Project Number: 48954
Want to contribute to this research?
We’re looking for participants who have been diagnosed with drug-resistant epilepsy (that means having ongoing seizures after two or more trials of medications), or are the treatment decision-makers for people living with drug-resistant epilepsy.
What’s involved?
- Participation in a 90 minute focus group on Zoom
- A discussion about treatment experiences and factors that influence decision-making
You may be eligible to participate if you:
- Have been diagnosed with drug-resistant epilepsy, or care for someone who has
- Are 18 years of age or older
- Live in Australia
- Can speak conversational English
Participants will receive a $50 gift voucher as reimbursement for their time.
-
-
Meet the team
Senior Study Coordinator
If you have any questions or need further assistance, please reach out to our Study Coordinator.
Alison Conquest - alison.conquest@monash.edu
Support
Angelini Pharma (Phase 1)